Literature DB >> 17508137

Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.

Ales Bartos1, Lenka Fialová, Jirina Soukupová, Jaromír Kukal, Ivan Malbohan, Jirí Pit'ha.   

Abstract

Neurofilaments are cytoskeletal proteins localized within axons, which may interact with the immune system during and following tissue destruction in multiple sclerosis (MS). Antibodies against the medium neurofilament subunit synthesized intrathecally may reflect axonal damage in MS patients. Both immunoglobulin G (IgG) and M (IgM) responses against the purified native medium subunit of neurofilaments (NFM) using enzyme-linked immunosorbent assay (ELISA) were determined in paired serum and cerebrospinal fluid samples obtained from 49 MS patients, 16 normal controls (CN), 21 control patients with miscellaneous diseases (CD) and 14 patients with neurodegenerative disorders (CDEG). Intrathecal production of IgM and IgG antibodies to NFM were elevated in MS patients compared with the CN or CD groups (p<0.04 for IgM, p<0.01 for IgG). The increase was present in all the MS courses (relapsing-remitting, primary and secondary progressive). Similar local anti-NFM IgG and IgM synthesis occurred in the MS and CDEG groups. MS patients with short and long disease duration did not differ in terms of their anti-NFM IgM and IgG responses. Repeated examinations showed stable intrathecal anti-NFM production. Intrathecal IgG and IgM antibodies against NFM were increased in MS patients and may serve as a potential marker for axonal pathology. The extent of anti-NFM levels did not correspond to any individualized clinical profiles of MS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508137     DOI: 10.1007/s00415-006-0185-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

Review 1.  B cells and antibodies in CNS demyelinating disease.

Authors:  A H Cross; J L Trotter; J Lyons
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

2.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.

Authors:  M A van Walderveen; W Kamphorst; P Scheltens; J H van Waesberghe; R Ravid; J Valk; C H Polman; F Barkhof
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Authors:  R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.

Authors:  Y K Semra; O A Seidi; M K Sharief
Journal:  J Neuroimmunol       Date:  2002-01       Impact factor: 3.478

6.  Anti-neurofilament antibodies in blood of patients with neurological diseases.

Authors:  D Karcher; B S Federsppiel; F D Lowenthal; F Frank; A Lowenthal
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

7.  Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

Authors:  J N Lycke; J E Karlsson; O Andersen; L E Rosengren
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

8.  Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

Authors:  Tanja Kuhlmann; Gueanelle Lingfeld; Andreas Bitsch; Jana Schuchardt; Wolfgang Brück
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

9.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

Authors:  M Filippi; M Bozzali; M Rovaris; O Gonen; C Kesavadas; A Ghezzi; V Martinelli; R I Grossman; G Scotti; G Comi; A Falini
Journal:  Brain       Date:  2003-02       Impact factor: 13.501

Review 10.  Neurofilaments and neurological disease.

Authors:  Ammar Al-Chalabi; Christopher C J Miller
Journal:  Bioessays       Date:  2003-04       Impact factor: 4.345

View more
  15 in total

1.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

2.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

Review 3.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

4.  Axonal damage in multiple sclerosis.

Authors:  Jeffery D Haines; Matilde Inglese; Patrizia Casaccia
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

5.  Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE.

Authors:  Marloes van Zwam; Ruth Huizinga; Marie-José Melief; Annet F Wierenga-Wolf; Marjan van Meurs; Jane S Voerman; Knut P H Biber; Hendrikus W G M Boddeke; Uta E Höpken; Christian Meisel; Andreas Meisel; Ingo Bechmann; Rogier Q Hintzen; Bert A 't Hart; Sandra Amor; Jon D Laman; Leonie A Boven
Journal:  J Mol Med (Berl)       Date:  2008-12-03       Impact factor: 4.599

Review 6.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis.

Authors:  Gurumoorthy Krishnamoorthy; Amit Saxena; Lennart T Mars; Helena S Domingues; Reinhard Mentele; Avraham Ben-Nun; Hans Lassmann; Klaus Dornmair; Florian C Kurschus; Roland S Liblau; Hartmut Wekerle
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

8.  Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum.

Authors:  L Fialová; J Švarcová; A Bartos; I Malbohan
Journal:  Folia Microbiol (Praha)       Date:  2012-05-08       Impact factor: 2.099

9.  NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.

Authors:  Dandan Li; Wenhao Zhao; Xinyu Zhang; Hanning Lv; Chunhong Li; Lichun Sun
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

10.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.